Literature DB >> 24619963

Early collection of saliva specimens from Bell's palsy patients: quantitative analysis of HHV-6, HSV-1, and VZV.

Ombretta Turriziani1, Francesca Falasca, Paola Maida, Aurelia Gaeta, Corrado De Vito, Patrizia Mancini, Daniele De Seta, Edoardo Covelli, Giuseppe Attanasio, Guido Antonelli.   

Abstract

Bell's palsy is the most common cause of facial paralysis. Although it has been associated with diabetes mellitus, hypertension, pregnancy, and preeclampsia, the etiology of Bell's palsy remains unknown. The reactivation of latent herpes simplex virus (HSV) or varicella-zoster virus (VZV) with subsequent inflammation and entrapment of the facial nerve in the narrow labyrinthine segment has been implicated as a cause of facial paralysis, but the active role of these viruses in Bell's palsy is still discussed. This study quantified HSV-1 DNA, VZV DNA, and HHV-6 DNA in 95 saliva samples collected from patients within 48 hr from the onset of paralysis. HSV-1, VZV, and HHV-6 were detected in 13%, 3%, and 61% of patients, respectively. The detection rate did not differ significantly between patients and a control group of healthy donors. Interestingly, however, the value of HHV-6 DNA copies was significantly higher than that detected in healthy donors. In addition, the mean value of HHV-6 DNA recorded in patients who had at least a one grade improvement of palsy at the first visit was significantly lower than that detected in patients who showed no change in facial palsy grade or an increase of at least one grade. These findings call into question the role of HSV-1 and VZV in the etiology of Bell's palsy, and suggest that HHV-6 may be involved in the development of the disease or that the underlying disease mechanism might predispose patients to HHV-6 reactivation.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  Bell's palsy; HHV6; HSV1; VZV

Mesh:

Substances:

Year:  2014        PMID: 24619963     DOI: 10.1002/jmv.23917

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  8 in total

1.  Comparison of acyclovir and famciclovir for the treatment of Bell's palsy.

Authors:  Ho Joong Kim; Sang Hoon Kim; Junyang Jung; Sung Su Kim; Jae Yong Byun; Moon Suh Park; Seung Geun Yeo
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-02-12       Impact factor: 2.503

2.  Is C-reactive protein to albumin ratio an indicator of poor prognosis in Bell's palsy?

Authors:  Serkan Cayir; Omer Hizli; Serkan Kayabasi
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-10-16       Impact factor: 2.503

3.  Concurrent pityriasis rosea and Bell's palsy.

Authors:  Vanessa Voss; Adam Mattox; Mary Guo
Journal:  BMJ Case Rep       Date:  2017-01-23

4.  Variation in human herpesvirus 6B telomeric integration, excision, and transmission between tissues and individuals.

Authors:  Michael L Wood; Colin D Veal; Rita Neumann; Nicolás M Suárez; Jenna Nichols; Andrei J Parker; Diana Martin; Simon Pr Romaine; Veryan Codd; Nilesh J Samani; Adriaan A Voors; Maciej Tomaszewski; Louis Flamand; Andrew J Davison; Nicola J Royle
Journal:  Elife       Date:  2021-09-21       Impact factor: 8.140

5.  Bell's palsy: symptoms preceding and accompanying the facial paresis.

Authors:  Daniele De Seta; Patrizia Mancini; Antonio Minni; Luca Prosperini; Elio De Seta; Giuseppe Attanasio; Edoardo Covelli; Andrea De Carlo; Roberto Filipo
Journal:  ScientificWorldJournal       Date:  2014-11-27

Review 6.  Facial Palsy, a Disorder Belonging to Influential Neurological Dynasty: Review of Literature.

Authors:  Ujwala R Newadkar; Lalit Chaudhari; Yogita K Khalekar
Journal:  N Am J Med Sci       Date:  2016-07

7.  Recurrent Bell's palsy: outcomes and correlation with clinical comorbidities.

Authors:  P Mancini; V Bottaro; F Capitani; G De Soccio; L Prosperini; P Restaino; M De Vincentiis; A Greco; G A Bertoli; D De Seta
Journal:  Acta Otorhinolaryngol Ital       Date:  2019-10       Impact factor: 2.124

Review 8.  Herpes simplex virus 2 infection: molecular association with HIV and novel microbicides to prevent disease.

Authors:  Paula A Suazo; Eduardo I Tognarelli; Alexis M Kalergis; Pablo A González
Journal:  Med Microbiol Immunol       Date:  2014-09-11       Impact factor: 3.402

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.